Floatz logo

DALPICICLIB ISETIONATE

Triple Negative Breast Cancer (TNBC)

Fudan UniversitySmall moleculePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
73/ 100

Competitive context

38 Active assets in the Triple Negative Breast Cancer (TNBC) cohort.

Asset / SponsorPhaseRating
Shr-A1811
Fudan University
Phase 3B
IERAMILIMAB
Novartis Pharmaceuticals
Phase 2B
b013
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3CCC
Tuvonralimab
Harbin Medical University
Phase 2/3CCC
Tenalisib
Rhizen Pharmaceuticals SA
Phase 2CCC

View all 50 →

Same molecule, other indications

DALPICICLIB ISETIONATE is also rated in:

Breast CancerDormant
BB
Indicative ·
66 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →
NeoplasmDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →